Enhanced Anti-MICA Antigen Binding Fragments and Fusion Molecules for Cancer Immunotherapy

This inventive concept introduces a suite of improvements to anti-MICA antigen binding fragments and fusion molecules, enhancing their binding affinity, stability, and efficacy in cancer immunotherapy.

The original patent disclosed anti-MICA antigen binding fragments and fusion molecules for cancer immunotherapy. However, these molecules had limitations in terms of binding affinity, stability, and efficacy. The new inventive concept addresses these limitations by introducing direct improvements and enhancements, resulting in more effective and efficient cancer treatment.

The new inventive concept comprises four key aspects: 1) a system for detecting MICA-expressing cells using a fusion molecule with enhanced binding affinity, 2) a method for enhancing the cytotoxic activity of T-cells against MICA-expressing cancer cells using a bi-specific T-cell engager, 3) a CAR-T cell therapy with improved stability and folding of the chimeric antigen receptor, and 4) a system for monitoring the efficacy of anti-MICA CAR-T cell therapy using a biosensor. These improvements enable more accurate detection, enhanced treatment efficacy, and better monitoring of treatment outcomes.

The new inventive concept introduces novel and non-obvious improvements to the original patent, including enhanced binding affinity, improved stability and folding, and innovative biosensor technology. These advancements provide a significant step forward in cancer immunotherapy, enabling more effective and efficient treatment of MICA-expressing cancer cells.

Alternative embodiments of the inventive concept could include using different types of fusion molecules, modifying the bi-specific T-cell engager to target other cancer markers, or developing new biosensor technologies to monitor treatment outcomes. These variations would ensure broad conceptual coverage and enable adaptation to different therapeutic contexts.

The enhanced anti-MICA antigen binding fragments and fusion molecules have significant commercial potential in the cancer immunotherapy market. The inventive concept could be licensed to biotech companies, used to develop new cancer therapies, or integrated into existing treatment regimens to improve patient outcomes.